Expert opinion on pharmacotherapy
Cure8 research brief
Why This Matters
Crohn's-like disease of the pouch is a meaningful complication after IPAA that can impair quality of life and risk pouch failure; knowing which drug classes show promise for specific pouch phenotypes can guide discussions with clinicians.
Who Should Pay Attention
adult-patients; post-surgery-patients; clinicians; researchers
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The article reports that management of CLDP is phenotype-driven (inflammatory, penetrating, fibrostenotic) and combines medical, endoscopic, radiologic, dietary, and surgical approaches.
Observational studies suggest strongest effectiveness signals for anti-TNF and interleukin-directed therapies for penetrating and fibrostenotic phenotypes, while vedolizumab may work better for inflammatory-predominant disease.
The review highlights widespread limitations: no randomized trials, inconsistent diagnostic criteria, and lack of phenotype-specific outcome reporting.
Keep In Mind
The review is phenotype-focused and notes limited high-quality trial data; consider that many conclusions are from observational studies and expert interpretation rather than randomized controlled trials.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationExpert opinion on pharmacotherapy
AuthorsLogan Kratzer, Miles P Sparrow, Zaid Ardalan
InstitutionDepartment of Gastroenterology, Alfred Health, Melbourne, Victoria, Australia.
Study typeJournal article, review
Indexed viaPubMed
Source typeResearch paper
PublishedAug 6, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...
Escalating Crohn's Care: The Case for Dual Therapy - Medscape
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...